Johnson & Johnson

JNJ-N

NYSE:JNJ

159.48
2.16 (1.34%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
April 13, 2021
This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.
Show full opinionHide full opinion
This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.
Gordon Reid
Price
$159.425
Owned
No
PAST TOP PICK
PAST TOP PICK
April 6, 2021
(A Top Pick Mar 12/20, Up 34%) A great company. Pharma, medical technology and consumer products are its three divisions, so if one lags, the others pick up the slack. Has great cash flow and pays an increasing yield. They came out with a Covid vaccine quickly. Developing drugs is a risk, because it depends on FDA approval, but JNJ operates three divisions to spread overall risk. He likes that, unlike pure pharma which depend on their drug pipeline.
Show full opinionHide full opinion
(A Top Pick Mar 12/20, Up 34%) A great company. Pharma, medical technology and consumer products are its three divisions, so if one lags, the others pick up the slack. Has great cash flow and pays an increasing yield. They came out with a Covid vaccine quickly. Developing drugs is a risk, because it depends on FDA approval, but JNJ operates three divisions to spread overall risk. He likes that, unlike pure pharma which depend on their drug pipeline.
Paul Harris, CFA
Price
$163.430
Owned
Yes
WATCH
WATCH
March 24, 2021
Has many brands that are billion dollar platforms. Consistent growth over last 25 years. High quality. Good positioning in consumer healthcare, pharma, and medical devices. On his focus list.
Show full opinionHide full opinion
Has many brands that are billion dollar platforms. Consistent growth over last 25 years. High quality. Good positioning in consumer healthcare, pharma, and medical devices. On his focus list.
TOP PICK
TOP PICK
March 16, 2021
It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)
Show full opinionHide full opinion
It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)
Christine Poole
Price
$161.370
Owned
Yes
BUY
BUY
March 15, 2021
They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.
Show full opinionHide full opinion
They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.
Jim Cramer - Mad Money
Price
$160.420
Owned
Unknown
SELL STRENGTH
SELL STRENGTH
March 12, 2021
Trades around 15x 2022, versus the market which is around 22x. A fine name to own with a decent dividend. Did very well during covid. He is looking to add to names that didn't do well during covid. It is not on his list for this reason. He would shave down and add money to more growth play.
Show full opinionHide full opinion
Trades around 15x 2022, versus the market which is around 22x. A fine name to own with a decent dividend. Did very well during covid. He is looking to add to names that didn't do well during covid. It is not on his list for this reason. He would shave down and add money to more growth play.
Greg Newman
Price
$159.600
Owned
Yes
TOP PICK
TOP PICK
March 3, 2021
Dividend growth of 57 consecutive years. 3 divisions, plus vaccine rollout. Operates like a tax on the consumer. Continues to tick along. Possible acquisitions, especially on the device side. Yield is 2.56%. (Analysts’ price target is $183.68)
Show full opinionHide full opinion
Dividend growth of 57 consecutive years. 3 divisions, plus vaccine rollout. Operates like a tax on the consumer. Continues to tick along. Possible acquisitions, especially on the device side. Yield is 2.56%. (Analysts’ price target is $183.68)
Darren Sissons
Price
$156.790
Owned
Yes
DON'T BUY
DON'T BUY
February 18, 2021
Very strong balance sheet, low debt to capital, a brand name. The only division that's clicking is pharma and the vaccine. Medical devices area has been hurt by Covid. Consumer side has taken a back seat, as many are buying generic brands. Talc litigation overhang.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
February 18, 2021
Very strong balance sheet, low debt to capital, a brand name. The only division that's clicking is pharma and the vaccine. Medical devices area has been hurt by Covid. Consumer side has taken a back seat, as many are buying generic brands. Talc litigation overhang.
Gordon Reid
Price
$165.730
Owned
No
BUY
BUY
February 5, 2021
Stock fell 4% when JNJ results results of their Covid vaccine A superb balance sheet, managers and product portfolio. Not concerned about their Covid vaccine results.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
February 5, 2021
Stock fell 4% when JNJ results results of their Covid vaccine A superb balance sheet, managers and product portfolio. Not concerned about their Covid vaccine results.
Jim Cramer - Mad Money
Price
$164.450
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
January 27, 2021
(A Top Pick Jan 08/20, Up 20%) Trades at 18x earnings and has increased its dividend for the last 54 years or so. They operate three businesses (personal care, pharmaceuticals, medical devices), so one segment lifts a sagging one, which is good. Has long owned this. He looks forward to their Covid vaccine phase 3 trial data in coming days. The vaccine won't make them a ton of money but will validate their R&D process. This stock will continue to do well.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 27, 2021
(A Top Pick Jan 08/20, Up 20%) Trades at 18x earnings and has increased its dividend for the last 54 years or so. They operate three businesses (personal care, pharmaceuticals, medical devices), so one segment lifts a sagging one, which is good. Has long owned this. He looks forward to their Covid vaccine phase 3 trial data in coming days. The vaccine won't make them a ton of money but will validate their R&D process. This stock will continue to do well.
Paul Harris, CFA
Price
$167.955
Owned
Yes
PAST TOP PICK
PAST TOP PICK
January 26, 2021
(A Top Pick Sep 29/20, Up 12.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ has achieved the $165 target. We recommend trailing up the stop up from $132 to $147 (just above the original recommended entry level).
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 26, 2021
(A Top Pick Sep 29/20, Up 12.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ has achieved the $165 target. We recommend trailing up the stop up from $132 to $147 (just above the original recommended entry level).
Stockchase Research
Price
$170.490
Owned
_N/A
BUY
BUY
January 22, 2021
They report Tuesday and he expects a strong report as well as reveal positive Covid vaccine results.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 22, 2021
They report Tuesday and he expects a strong report as well as reveal positive Covid vaccine results.
Jim Cramer - Mad Money
Price
$163.550
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
January 8, 2021
(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of $148. Would wait for a pullback to enter.
Show full opinionHide full opinion
(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of $148. Would wait for a pullback to enter.
Chris Blumas
Price
$160.100
Owned
Yes
BUY
BUY
January 4, 2021
Biden will protect Obamacare, which spells great news managed care companies. Healthcare will continue to be a major theme this year. JNJ especially is well-positioned for earnings, new products and their eventual vaccine.
Show full opinionHide full opinion
Biden will protect Obamacare, which spells great news managed care companies. Healthcare will continue to be a major theme this year. JNJ especially is well-positioned for earnings, new products and their eventual vaccine.
Jim Cramer - Mad Money
Price
$156.500
Owned
Unknown
DON'T BUY
DON'T BUY
December 7, 2020
The healthcare sector in general has been in the news a lot recently. He owned this one a couple of years ago. It is a diversified, broad exposure to pharma. There are, however, sectors of healthcare he likes better such as managed health care and devices.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 7, 2020
The healthcare sector in general has been in the news a lot recently. He owned this one a couple of years ago. It is a diversified, broad exposure to pharma. There are, however, sectors of healthcare he likes better such as managed health care and devices.
Bryden Teich
Price
$148.970
Owned
No
Showing 1 to 15 of 480 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 16

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 8

Total Signals / Votes : 26

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 26 stock analysts published opinions about JNJ-N. 16 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by Gordon Reid on 2021-04-13. Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

26 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2021-04-13, Johnson & Johnson (JNJ-N) stock closed at a price of $159.48.